RxDoctor Payments Data

Jeremy Belch

Obstetrics & Gynecology · New Bern, NCNPI 1750657284

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,565 of the $6,963 with a category attached, or 94.3%. Sonio accounts for 93.9% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2024 at $6,701 and has fallen 99.1% since, to $62 in 2025. Among obstetrics & gynecology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,963in general payments, 2019–2025

Across 25 payments — averaging $278.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sonio$7K
  • Pfizer$93
  • Biogen$53
  • Medtronic$43
  • Novo Nordisk$35
  • Seqirus USA Inc$26
  • plus $172 from 10 others
$16,348in research payments, 2019–2025

Across 8 payments — averaging $2043.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sumitomo Pharma America, Inc.$15K
  • Astellas Pharma Global Development$2K

What the payments were for

  • Consulting fees$6,56594%
  • Food & beverage$3986%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,963 in reported general payments places this provider in the 90th percentile of 1,344 obstetrics & gynecology providers in North Carolina.

See all obstetrics & gynecology providers in North Carolina

Medicare billing

Part B allowed, 2024
$45,723
Medicare patients
188
Services billed
552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VeozahFezolinetant17$13,068
Estradiol76$4,189
Clobetasol Propionate22$718
Cyclobenzaprine Hcl11$371
ValacyclovirValacyclovir Hcl18$307
Medroxyprogesterone Acetate15$232
Gabapentin11$173
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst14$158
Fluconazole22$147
Duloxetine Hcl13$27

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncVeozah$20$13,06817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,344 obstetrics & gynecology providers in North Carolina.

Other obstetrics & gynecology in New Bern

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →